WHY AREN’T PEOPLE with depression prescribed magic mushrooms instead of Zoloft or Prozac?
Exploring the companies and themes that make up this emerging and exciting new sector
Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP
Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
California Bill To Legalize Possession Of Psychedelics Clears Second Senate Committee
A second California Senate committee has approved a bill to legalize possession of a wide range of psychedelics and create a working group to study broader reform.
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.
Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Mydecine commences screening psilocybin-based drug candidates.
Breaking News: MINDCURE (CSE: MCUR | OTC: MCURF) Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform
Utilizing Speak Ai’s technology, iSTRYM will provide-AI-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
Cybin prepares two drug candidates, CYB003 and CYB004 for Investigational New Drug applications.
How Cannabis Became the Gateway Drug…For Psychedelic Drug Normalization
Forty years ago, cannabis was labelled "a Gateway Drug" to harder drug use -- such as psychedelics. Today, cannabis is the Gateway Drug to psychedelics legalization.
Peter Thiel-Backed Psychedelics Firm Buys Majority of Brain-Control Interface Firm
ATAI Life Sciences, a biosciences company backed by venture capitalist and freedom-loving billionaire Peter Thiel that specializes in experimental treatment of mental disorders with psychedelic drugs, has bought out a majority stake in a company working to meld the mind with machines.
The Mental Health Crisis: A Pandemic Becomes A Catastrophe
Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
MINDCURE increases its strategic investment in ATMA Journey Centers and deploys its iSTRYM digital therapeutics platform.